evidence boundary
supportsexperimental
An evidence atom is an inspectable support unit. It is not a finding by itself; it supports or challenges a finding through review.
frontiers / frontier
Evidence atom
back to sourcesevidence boundary
supportsAn evidence atom is an inspectable support unit. It is not a finding by itself; it supports or challenges a finding through review.
finding binding
boundVerubecestat failed to improve cognition or function in mild-to-moderate Alzheimer's disease despite BACE1 target engagement.
inspect finding →
source binding
source-boundvs_10993e8203d14020
inspect source →
review context
unverified5 reviewable changes and 0 evaluation records target this atom or its bound objects.
Evidence statement
Verubecestat failed to improve cognition or function in mild-to-moderate Alzheimer's disease despite BACE1 target engagement.
locator
source:Egan et al. 2018 NEJM, EPOCH|section:curator_source
extraction method
manual_curation
support relation
supports
condition refs
vcnd_5e8a6ea75cba6f3a
Caveats
No evidence-specific caveats are recorded.
events
vev_256faa62a301a60cfinding.reviewedReviewed as amyloid-pathway translation tension, not as a direct antibody contradiction.
reviewer:will-blair-bot · 2026-05-06
vev_54acd1bb09b776e3finding.caveatedBACE failures should not be treated as proof that every amyloid-lowering approach fails.
reviewer:will-blair-bot · 2026-05-06
vev_d5fc4a90bfc01935finding.caveatedDecision-console scope: verubecestat is used here as a failed BACE program exemplar; the correction path should not generalize this single result to every amyloid-lowering approach.
reviewer:will-blair-bot · 2026-05-06
vev_e18f2033f68a422ffinding.reviewedReviewed for decision-console use: failed BACE program claim is scoped to verubecestat EPOCH-style clinical failure, not all anti-amyloid mechanisms.
reviewer:will-blair-bot · 2026-05-06
vev_ea98c3207e67eb18finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_371b4e01866e4d94finding.reviewReviewed for decision-console use: failed BACE program claim is scoped to verubecestat EPOCH-style clinical failure, not all anti-amyloid mechanisms.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_47e89f04337c7786finding.caveatDecision-console scope: verubecestat is used here as a failed BACE program exemplar; the correction path should not generalize this single result to every amyloid-lowering approach.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_7420a100feb4fe3ffinding.caveatBACE failures should not be treated as proof that every amyloid-lowering approach fails.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_942ae202f8fa3144finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_da34872d64ddd2c9finding.reviewReviewed as amyloid-pathway translation tension, not as a direct antibody contradiction.
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation rows are attached.